USPTO 2015–2025 USPTO PatentsView US Corporation

Sorrento Therapeutics, Inc.

USPTO PatentsView assignee record - 110 granted patents across 19 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

110

Total patents granted

CPC technology areas

16.4

Avg claims per patent

+39%

5-year filing velocity

The verdict

Sorrento holds 110 US patents across 19 technology areas, rank #3,383 of 50,000 tracked assignees.

#3,383
of 50,000 US assignees by volume: Top 27%
by Innovation Score (43.9/100): 16.4
avg claims per patent: +39%
filing velocity, last 5 yrs

Portfolio overview

Sorrento Therapeutics, Inc. has been granted 110 US utility patents between 2015 and 2024, placing Sorrento Therapeutics, Inc. at rank #3,383 across all assignees tracked by PlainPatent. This portfolio spans 19 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.4 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Sorrento Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Sorrento sits between OJI Holdings Corporation (110 patents, rank #3,379) and 8 Rivers Capital, Llc (109 patents, rank #3,387) - the closest US assignees by grant volume. The composite Innovation Score of 43.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 64 grants, compared with 46 in the 2015–2019 window, a +39% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Sorrento Therapeutics, Inc.'s 16.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 19 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sorrento Therapeutics, Inc. against peers pursuing similar technology classes.

OJI Holdings

110
Op-hygiene IP

110
Safran Ceramics

110
Shanghai Micro Eq…

110
The ADT Security

110
The Western Union

110
West Pharmaceutic…

110
Sorrento Therapeu… ◀

110
8 Rivers Capital

109

What this shows Sorrento holds 110 patents at rank #3,383, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sorrento

By rank, the assignees closest to #3,383 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Sorrento's primary technology class.

Sorrento's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

44 Top 27% higher than 73% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sorrento Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	1.8%
2016	2	1.8%
2017	4	3.6%
2018	17	15.5%
2019	21	19.1%
2020	18	16.4%
2021	24	21.8%
2022	8	7.3%
2023	9	8.2%
2024	5	4.5%

Which technologies does Sorrento Therapeutics, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 68

C07K - PEPTIDES 68

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 57

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 37

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 7

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 5

A61L - METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES 4

A61F - FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS 4

B29L - INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES 4

B29C - SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING 4

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 4

B29K - INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR ; MOULDS, ; REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS 4

B01D - SEPARATION 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 2

Top 15 of 19 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Growing

Where it ranks

Overall rank by patents

#3,383

Across all tracked assignees

Innovation Score

43.9 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Sorrento Therapeutics, Inc. hold?

Sorrento Therapeutics, Inc. holds 110 US granted patents filed between 2015 and 2024, spanning 19 technology areas.

What is Sorrento Therapeutics, Inc.'s Innovation Score?

Sorrento Therapeutics, Inc. has an Innovation Score of 43.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sorrento Therapeutics, Inc. focus on?

Sorrento Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 68 patents. The company has filed patents in 19 CPC subclasses total.

Is Sorrento Therapeutics, Inc.'s patent filing rate increasing or decreasing?

Sorrento Therapeutics, Inc.'s recent filing velocity is +39% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Sorrento Therapeutics, Inc.'s patents?

Sorrento Therapeutics, Inc.'s patents average 16.4 claims each. This falls within the standard range, providing solid legal coverage.

How is the Sorrento Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Sorrento's 110 grants land it in the top 27% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Sorrento ranks #3,383 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.